An abundance of evidences indicated that inhibition TLR4/NF-κB signaling pathway activation was a target to treat ALI (Chen et al., 2018b; Tan et al., 2018; Liu et al., 2019b). This evidence concerns the gene NFKB1 and acute respiratory distress syndrome.